Role of pharmacokinetic-pharmacodynamic principles in rational and cost- effective drug development

Therapeutic Drug Monitoring

Volumn 18, Issue 4, 1996, Pages 423-428

  Lieberman, Ronald ^a   McMichael, John ^b  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Cost effective drug development; Pharmacodynamics; Pharmacokinetics

Indexed keywords

BETAXOLOL; CYCLOSPORIN A; TACROLIMUS;

ANTIHYPERTENSIVE ACTIVITY; BETA ADRENERGIC RECEPTOR BLOCKING; CLINICAL TRIAL; COMPUTER MODEL; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG EFFICACY; DRUG MONITORING; ESSENTIAL HYPERTENSION; GRAFT REJECTION; HUMAN; IMMUNOMODULATION; LIVER TRANSPLANTATION; NEPHROTOXICITY; PRIORITY JOURNAL;

ARTIFICIAL INTELLIGENCE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; HUMANS;

EID: 0029817320     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199608000-00019     Document Type: Conference Paper

References (11)

1. Fung J, Todo S, Tzakis A, et al. Conversion of liver allograft recipients from cyclosporine to FK-506 based immunosuppression: benefits and pitfalls. Transplant Proc 1991;23: 14-21.
2. Lieberman R, Nelson R. Dose-response and concentration-response relationships: clinical and regulatory perspectives. Ther Drug Monit 1993;15:498-502.
3. The U.S. Multicenter FK 506 Liver Study Group. A comparison of tacrolimus (FK-506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994:331: 1110-5.
4. Japanese FK506 Study Group. Japanese study of FK-506 on kidney transplantation: results of late phase 2 study. Transplant Proc 1993;25:649-54.
5. The European FK 506 Multicentre Liver Study Group (writing committee: Neuhaus P, Pichlmayr R, Williams R). Randomised trial comparing tacrolimus (FK-506) and cyclosporin in prevention of liver allograft rejection. Lancet 1994;344: 423-8.
6. McMichael J, Lieberman R, Doyle H, et al. An intelligent and cost-effective computer dosing system for individualizing FK-506 therapy in transplantation and autoimmune disorders. J Clin Pharmacol 1993;33:599-605.
7. McMichael J, Lieberman R, Doyle H, et al. Computer-guided concentration-controlled trials in autoimmune disorders. Ther Drug Monit 1993;15:510-3.
8. Lieberman R, Ludden T, McMichael J, et al. Pharmacodynamic models, intermediate (surrogate) endpoints and computer simulations: an analysis of dose and concentration controlled trial designs. In: Anderson JG, Katzper M, eds. Simulation in the health sciences. SCS Press, San Diego, CA. 1994:137-42.
9. McMichael J, Lieberman R, McCauley J, et al. Computer-guided randomized concentration-controlled trials of tacrolimus in autoimmunity: multiple sclerosis and primary biliary cirrhosis. Ther Drug Monit 1996;18:435-7.
10. McMichael J, Lieberman R, Ramos H, et al. Physician experience vs computer learning: the efficiency of artificial intelligence learned optimal dosing of cyclosporine and tacrolimus in transplantation. In: Anderson JG, Katzper M, eds. Health sciences, physiological and pharmacological simulation studies. SCS press, San Diego, CA. 1995:194-8.
11. Lieberman R. FK-506, artificial intelligence and pharmacoeconomics. J Clin Pharmacol 1993;33:596-8.